Online inquiry

IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2217MR)

This product GTTS-WQ2217MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL15RA gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001243539.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3601
UniProt ID Q13261
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2217MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4627MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ12376MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ15111MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ4070MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ7851MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ12549MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ15449MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ2098MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AIN457
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW